Results 171 to 180 of about 134,000 (307)

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou, Maria Marketou, Maria Aktsiali, Ioannis Griveas   +3 more
wiley   +1 more source

Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020-2024). [PDF]

Biomolecules
Chatzipieris FP, Petsas E, Lambrinidis G, Matsoukas JM, Mavromoustakos T.   +4 more
europepmc   +1 more source

The Influence of Antibodies against Angiotensin II Type-1 Receptor on the Outcome of Kidney Transplantation: A Single-Center Retrospective Study. [PDF]

J Clin Med, 2023
Filiopoulos V, Vittoraki A, Vallianou K, Bellos I, Markaki P, Liapis G, Marinaki S, Iniotaki A, Boletis IN.   +8 more
europepmc   +1 more source

The Third Cytoplasmic Loop of the Angiotensin II Type 1 Receptor Exerts Differential Effects on Extracellular Signal–Regulated Kinase (ERK1/ERK2) and Apoptosis via Ras- and Rap1-Dependent Pathways [PDF]

, 2000
Judith Haendeler, Mari Ishida, László Hunyady, Bradford C. Berk   +3 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis. [PDF]

RMD Open
van der Wouden KE, Ahmed S, van Oostveen WM, Hoekstra EM, Liem SIE, Huizinga TWJ, Toes REM, Voskuyl AE, Riemekasten G, Fehres CM, Vonk M, de Vries-Bouwstra JK.   +11 more
europepmc   +1 more source

Atrial Electrical Remodeling in Mice With Cardiac-Specific Overexpression of Angiotensin II Type 1 Receptor. [PDF]

J Am Heart Assoc, 2022
Demers J, Ton AT, Huynh F, Thibault S, Ducharme A, Paradis P, Nemer M, Fiset C.   +7 more
europepmc   +1 more source

Activating types 1 and 2 angiotensin II receptors modulate the hypertrophic differentiation of chondrocytes

, 2014
一郎 墳本
openalex   +1 more source

Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV. [PDF]

Fundam Clin Pharmacol
Deminice R, Cella PS, Borsari AL, Padilha CS, de Oliveira VHF.   +4 more
europepmc   +1 more source

Angiotensin II type 1 receptor localizes at the blood-bile barrier in humans and pigs. [PDF]

Histochem Cell Biol, 2022
Pryymachuk G, El-Awaad E, Piekarek N, Drebber U, Maul AC, Hescheler J, Wodarz A, Pfitzer G, Neiss WF, Pietsch M, Schroeter MM.   +10 more
europepmc   +1 more source